정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 632 | Recruiting | Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults | Older Adults | Biological: COVID-19 Vaccine | Phase 4 | Beijing 302 Hospital, People's Hospital of Hunyuan County, Shanxi Province | OTHER | 300 | All | 18 Years ~ 80 Years | 302 Hospital, Beijing, China |
| 631 | Recruiting | Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers | COVID-19 Immunisation | Biological: COVID-eVax Device: Cliniporator® and EPSGun |
Phase 2 | Takis, Rottapharm Biotech | INDUSTRY | 160 | All | 18 Years ~ 65 Years | San Gerardo Hospital, Monza, Italy Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy INMI Lazzaro Spallanzani, Rome, Italy |
| 630 | Active, not recruiting | Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19 | COVID-19 | Biological: COVI-VAC Other: Placebo |
Phase 1 | Codagenix, Inc | INDUSTRY | 48 | All | 18 Years ~ 30 Years | hVIVO, London, United Kingdom |
| 629 | Recruiting | Safety and Immunogenicity of EXG-5003 | COVID-19 | Biological: EXG-5003 Biological: Placebo |
Phase 2 | Fujita Health University, Elixirgen Therapeutics, Inc. | OTHER | 60 | All | 20 Years ~ 55 Years | Fujita Health University Hospital, Toyoake, Aichi, Japan |
| 628 | Active, not recruiting | Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals | SARS-CoV-2 | Drug: GX-19N | Phase 1 | Genexine, Inc. | INDUSTRY | 30 | All | 55 Years ~ 85 Years | Severance hospital, Seoul, Korea, Republic of Gangnam Severance hospital, Seoul, Korea, Republic of |
| 627 | Not yet recruiting | Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 | COVID-19 | Drug: LNP-nCOV saRNA-02 Vaccine | Phase 1 | MRC/UVRI and LSHTM Uganda Research Unit | OTHER | 42 | All | 18 Years ~ 45 Years | MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda |
| 626 | Recruiting | Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection | Seroconversion | Biological: SARS-Cov-2 neutralizing antibody titer | Phase 3 | Zagazig University | OTHER_GOV | 140 | All | 18 Years | Zagazig University Faculty of Medicine, Zagazig, Sharkia, Egypt |